Acute lymphoblastic leukemia in children: An update of clinical, biological, and therapeutic aspects

Critical Reviews in Oncology and Hematology

Volumn 10, Issue 2, 1990, Pages 131-164

  Miller, Denis R ^a   Miller, Linda Patricia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER RISK; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME ABERRATION; HUMAN; IMMUNOPHENOTYPING; REVIEW;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; FEMALE; GENE REARRANGEMENT; HUMAN; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; ONCOGENES; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TUMOR STEM CELLS; UNITED STATES;

EID: 0025315740     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(90)90004-C     Document Type: Article

References (365)

1. Acute lymphoblastic leukemia in children: current status, controversies and future perspectives
2. The environment and disease: association or causation
3. Causation and disease: a chronological journey
4. Inferring causal relationships: elaboration of the criterion of “dose-response”
5. Epidemiology of acute lymphoblastic leukemia
6. Cytogenetic evidence of the intrauterine origin of acute leukemia in monozygotic twins
7. Lymphoblastic leukaemia in Siamese twins evidence for identity
8. Is spontaneous mutation the ‘cause’ of childhood acute lymphoblastic leukaemia?
9. Prenatal x-ray exposure and cancer in children
10. Influence of age at time of irradiation on induction of leukemia and ovarian tumors in RF mice
11. Childhood cancer in relation to prenatal exposure to atomic bomb radiation
12. Prenatal x-ray exposure and childhood cancer in twins
13. Childhood leukemias associated with fallout from nuclear testing
14. Electrical wiring configurations and childhood cancer
15. Electrical wiring configurations and childhood leukemia in Rhode Island
16. Case-control study of childhood cancer and exposure to 60-Hertz electric and magnetic fields
17. Malignant non-Hodgkin's lymphoma in children
18. Associations between influenza during pregnancy and childhood leukaemia
19. Childhood lymphatic leukemia: prenatal seasonality and possible association with congenital varicella
20. Excess leukemia in cohorts of children born following influenza epidemics
21. Incidence of neoplasms in children born after influenza epidemics
22. Occupational factors in the epidemiology of chemically induced lymphoid and hemopoietic cancers
23. Mortality among rubber workers: relationship to specific jobs
24. Benzene hematotoxicity and leukemogenesis
25. Benzene and leukemia. An epidemiological risk assessment
26. Benzene: epidemiologic observations of leukemia by cell type and adverse health effects associated with low level exposure
27. Blood dyscrasias and childhood tumors and exposure to chlordane and heptachlor
28. Mortality of workers employed in the manufacture of chlordane and heptachlor
29. Mortality studies of aluminum reduction plant workers: potroom and carbon department
30. Epidemiological studies of the occupational hazards of anesthesia. A review
31. Asbestos-associated neoplasms of B cell lineage
32. Asbestos exposure and lymphomas of the gastrointestinal tract and oral cavity
33. Leukaemia mortality in electrical workers in England and Wales
34. A cohort study of mortality and cancer incidence in ethylene oxide production workers
35. Epidemiologic relationships of the bovine population and human leukemia in Iowa
36. Farming and mortality from non-Hodgkin's lymphoma: a case-control study
37. Human leukemia: genetic and environmental clusters
38. Eleven sites of cancer in black gold miners from Southern Africa: A geographical inquiry
39. A case-control study of coccupational exposures and leukaemia
40. Cancer mortabity in metal workers
41. Cause-specific mortality among newspaper web pressmen
42. Increased risk of developing acute leukemia after employment as a painter
43. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols, and phenoxy acids: a case control study
44. Cancer mortality among printing plant workers
45. Occupational factors in the epidemiology of leukemia in Hiroshima and Nagasaki
46. A mortality survey of employees engaged in the development or manufacture of styrene-based products
47. Observations of the site-specific carcinogenicity of vinyl chloride to humans
48. Cancer mortality among woodworkers
49. Lymphocytic leukemia and exposures to benzene and other solvents in the rubber industry
50. An evaluation of the associations of leukemia and rubber industry solvent exposure
51. Association of leukemia with radium groundwater contamination
52. An analysis of contaminated well water and health effects in Woburn Massachusetts
53. Ranking possible carcinogenic hazards
54. Trichloroethylene: an update
55. The need for biological risk assessment in reaching decisions about carcinogens
56. Dose relationships for carcinogens: a review
57. Spatial clustering in childhood leukemia
58. Some epidemiological aspects of leukemia in children
59. Effect of smoking during pregnancy on the risk of cancer in children
60. A survey of childhood malignancies
61. Maternal smoking during pregnancy and risk of childhood cancer
62. Cancer risk in adulthood from early life exposure to parents smoking
63. Cigarette smoking and leukemia
64. Tumors and hyperplastic lesions in Syrian hamsters following transplacental and neonatal treatment with cigarette smoke condensate
65. Occupations of father at time of birth of children dying of malignant diseases
66. Cancer in the offspring of fathers in the hydrocarbon-related occupations
67. Association of childhood leukemia with matermal age, birth order, and parental occupation
68. Childhood leukemia and parental occupation: a register based case control study
69. Infant leukemia and parental exposure to motor vehicle exhaust fumes
70. Parental occupations and cancer in children
71. Childhood leukemia and parents: occupational and home exposures
72. Offspring of long-time survivors of childhood cancer
73. Chemical carcinogenesis: a current biological perspective
74. Lymphomas in persons with naturally occurring immunodeficiency disorders
75. Speculations on the cause of childhood acute lymphoblastic leukemia
76. Pre-B cells in mouse bone marrow: immunofluorescence stathmokinetic studies of proliferation of cytoplasmic u chain bearing cells in normal mice
77. Fidelity of DNA synthesis
78. Carcinogenes. Rare recombinants instead of altered oncogenes (a review)
79. Differentiation-linked leukemogenesis in lymphocytes
80. The ontogeny and organization of the lymphoid system
81. The interregional epidemiological study of childhood cancer (IR ESCC): a case control study of aetiologic factors in leukaemia and lymphoma
82. Childhood leukemia and infectious diseases in the first year of life: a register based case control study
83. Immunizations against infectius diseases and childhood cancers
84. Immortalized B lymphocytes produce B cell growth factors
85. Epstein-Barr virus induced lymphoproliferation
86. The epidemiology of Burkitt's lymphoma: evidence for a causal association with Epstein-Barr virus
87. Transcriptional activation of an unrearranged and untranslocated c-myc oncogene by translocation of a c locus in Burkitt lymphoma cells
88. Human c-myconcogene is located in the region of chromosome B that is translocated in Burkitt lymphoma cells
89. Chromosome translocations in B and T cell neoplasias
90. Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation
91. Identification and molecular cloning of the human B-lym transforming gene activated in Burkitt's lymphoma
92. Acute lymphoblastic leukaemia of B cell origin in an anti-HIV positive intravenous drug abuser
93. An EBV genome carrying pre-B cell leukaemia in a homosexual man with characteristic karyotype and impaired EBV-specific immunity
94. Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA)
95. Detection of the common acute lymphoblastic leukemia antigen (CALLA) on B cells from human fetal tissues: a multiple phenotypic characterization
96. Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry
97. Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens
98. Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens
99. Chemical leukemogenesis: benzene as a model
100. Les leucoses benzeniques
101. The cytochromes P448 — a unique family of enzymes involved in chemical toxicity and carcinogenesis
102. Covalent binding of benzene and its metabolites to DNA in rabbit bone marrow mitochondria in vitro
103. Metabolism of benzene and its metabolites in bone marrow
104. Effects of short-term benzene administration on bone marrow cell cycle kinetics in the rat
105. Quinones as toxic metabolites of benzene
106. Acute toxicity of benzene inhalation in hemopoietic precursor cells
107. The detection of in vitro hematotoxicity of benzene by in vitro liquid bone marrow cultures
108. Acute and chronic dose response effects of inhaled benzene on multipotential hemopoietic stem cells (CFU-S) and granulocyte/macrophage progenitors (GM-CFU-C) cells in CD-1 mice
109. Benzene hematotoxicity and leukemogenesis
110. Repeated exposure of C57B1/mice to inhaled benzene at 10 ppm markedly depressed erythropoietic colony formation
111. Evidence for hematotoxicity and tumorigenesis in rats exposed to 1009 ppm benzene
112. Depressions in B and T lymphocyte mitogen-induced blastogenesis in mice exposed to low concentrations of benzene
113. Effect of benzene metabolites on PHA stimulated lymphopoiesis in rat bone marrow
114. Cytogenetic effects of inhaled benzene in murine bone marrow. Induction of sister chromatid exchanges, chromosomal aberrations, and cellular proliferation inhibition in DBA/2 mice
115. Benzene myeloclastogenicity: a function of its metabolism
116. Possible involvement of unstable sites in chromosomes 7 and 14 in human cancer
117. Biochemical and molecular indicators of carcinogen exposure DNA damage and genetic predisposition
118. The role of oncogenes in chemical carcinogenesis
119. Direct mutagenesis of H-ras-1 oncogenes by nitroso-methyl-urea during initiation of mammary carcinogenesis in rats
120. Structural organization of the bcr gene and its role in the Ph′ translocation
121. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
122. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia
123. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia
124. Bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia
125. Heterogeneity of chromosome 22 breakpoint in Ph-positive acute lymphocytic leukemia
126. Philadelphia chromosome-positive acute lymphoblastic leukemia: detection of a DNA rearrangement 50–250 kilobase proximal to BCR
127. A novel c-abl protein produced in Philadelphia-positive acute lymphoblastic leukaemia
128. Unique forms of the abl tyrosine kinase distinguish Ph′ positive CML from Ph′ positive ALL
129. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia
130. The abl oncogene in human leukemias
131. The molecular genetics of cancer: 1988
132. A viral long terminal repeat in the interleukin 2 gene of a cell line that constitutively produces interleukin 2
133. Constitutive synthesis of interleukin-3 by leukaemia cell line WEH1-3B is due to retroviral insertion near the gene
134. Interactions of oncogenes with hematopoietic cells
135. The human gene map
136. Effects of maternal age and birth order on the risk of mongolism and leukemia
137. Neonatal leukemoid reactions: an isolated manifestation of mosaic trisomy 21
138. Treatment of neonatal leukemoid reactions in mosaic trisomy 21
139. Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis
140. Transient myeloproliferative disorder and acute nonlymphoblastic leukemia in Down's syndrome
141. The myeloproliferative reaction in a child with Down's syndrome. Cytological and chromosomal evidence for a transient leukemia
142. Chromosomal abnormalities in acute lymphoblastic leukemia Structural and numerical changes in 234 cases
143. Leukemia and other cancers, anomalies, and infections in causes of death in Down's syndrome in the United States during 1976
144. Susceptibility to leukemic immunologic factors in Down's syndrome
145. Proliferative kinetics and chromosome damage in trisomy 21 lymphocyte cultures exposed to gamma rays and bleomycin
146. The ets sequence from the transforming gene of avian erythroblastosis virus E26 has unique domains on human chromosome 11 and 21, both are transcriptionally active
147. Hu-ets-1 and Hu-ets-L genes are transposed in acute leukemias with (4;11) and (8;21) translocations
148. Fragile sites and predisposition to leukemia and lymphoma
149. A point mutation at codon 13 of the n-ras oncogene in myelodysplastic syndrome
150. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia
151. Epidemiological factors and survival experience in 1770 children with acute leukemia
152. Morphological criteria for prognostication of acute lymphoblastic leukemia
153. Search for correlations between cytological types and therapeutic sensitivity of acute leukemias
154. Cytological classification of acute leukemias; a survey of 1400 cases
155. Cytomorphological determinants of prognosis in acute lymphoblastic leukemia of children
156. Proposals for the classification of the acute leukemias
157. A score at diagnosis for predicting length of remission in childhood acute lymphoblastic leukaemia
158. Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukmia (ALL)
159. Subclassification of acute lymphoblastic leukemia in children: analysis of reproducibility of morphologic criteria and prognostic implications
160. Morphological diagnosis in childhood leukemia
161. Correlation of the FAB morphologic criteria and prognosis in acute lymphoblastic leukemia of childhood
162. Immunologically defined subclasses of acute lymphoblastic leukemia in children: their relationship to presentation features and prognosis
163. Prognosis and treatment of acute lymphoblastic leukemia
164. Acute lymphoblastic leukemia in children: immunologic, cytochemical, morphologic and cytogenetic studies in relation to pretreatment risk factors
165. The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia
166. The morphological classification of acute lymphoblastic leukemia: concordance among observers and clinical correlations
167. Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group
168. The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia
169. French American British (FAB) morphological classification of childhood lymphoblastic leukaemia and its clinical importance
170. Relationship of blast cell surface markers and morphology (FAB classification) in childhood acute lymphoblastic leukemia
171. t(8;14) Translocation in a Burkitt's type of lymphoblastic leukemia (L3)
172. Acute lymphoblastic leukemia with Burkitt cell morphology and cytoplasmic immunoglobulin
173. Acute B-lymphocytic leukemia with L1 morphology: a report of two pediatric cases
174. Unfavorable prognostic significance of hand-mirror cells in childhood acute lymphoblastic leukemia: a report from Childrens Cancer Study Group
175. Acute inclusion body leukemia: case report and review of literature
176. Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia
177. DNA and RNA determinations of 111 cases of childhood acute lymphoblastic leukemia (ALL) by flow cytometry. Correlation of FAB classification with DNA stemline and proliferation
178. A morphometric classification of acute lymphoblastic leukemia in children
179. The computer-assisted morphological classification of acute leukemia. I. Preliminary results
180. Computer assisted digital image analysis of FAB morphology in childhood acute lymphoblastic leukemia (ALL)
181. Immunological classification of leukemia and lymphoma
182. Cell surface markers in hematologic malignancies
183. Blast-2 (EBVCS), an early cell surface marker of human B cell activation is superinduced by Epstein-Barr virus
184. Expression and function of an early activation marker restricted to human B cells
185. Identification of an early activation antigen (Bac-1) on human B cells
186. Selective expression of the common acute lymphoblastic leukemia (GP 100) antigen on immature cells and their malignant counterparts
187. Phenotypic similarities and differences between CALLA-positive acute lymphoblastic leukemia cells and normal bone marrow CALLA-positive B cell precursors
188. Expression of common acute lymphoblastic leukemia antigen (CALLA) in human malignant melanoma cells
189. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B cells
190. Differentiation linked gene rearrangement and expression in acute lymphoblastic leukemia
191. Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells
192. The human T-cell receptor. Structure and function
193. Gene rearrangement as markers of clinical variation and minimal residual disease in acute lymphoblastic leukemia
194. Rearrangements of immunoglobulin chain genes in T cell acute lymphoblastic leukemia
195. B-cell origin of non-T cell lymphoblastic leukemia
196. HD39(B3), a B lineage restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes
197. A analysis of clinical and laboratory features of acute lymphoblastic leukemias with emphasis of 35 children with pre-B leukemia
198. Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells
199. Chromosomal translocations in B and T cell neoplasms
200. Monoclonal antibody characterization of surface antigens in childhood T cell lymphoid malignancies
201. An alternative pathway of T cell activation: a functional role for the 50kD T11 sheep erythrocyte receptor protein
202. Discrete stages of human intrathymic differentiation. Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage
203. Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies
204. Characterization of a suppressor cell leukemia: evidence for the requirement of an interaction of two cells in the development of human suppressor effector cell
205. The isolation and characterization of the human helper inducer T cell subset
206. The isolation and characterization of the human suppressor inducer T cell subset
207. Functional and phenotypic studies of Japanese adult T cell leukemia cells
208. Lineage heterogeneity in acute leukaemia: acute mixed lineage leukaemia and lineage switch
209. Acute leukemia with two cell populations of lymphoblasts and monoblasts
210. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance
211. Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis
212. Biphenotypic leukemia: immunologic and morphologic evidence for a common lymphoid-myeloid progenitor in humans
213. Acute leukemia with mixed lymphoid and myeloid phenotype
214. Lineage switch in acute leukemia
215. The E-rosette-associated antigen of T-cells can be identified on blasts from patients with acute myeloblastic leukemia
216. Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis
217. Rearrangement of T-cell receptor B-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia childhood
218. Heavy chain immunoglobulin gene rearrangement in acute non-lymphocytic leukemia
219. Analysis of the clinical and biological significance of lymphoid phenotypes in acute leukemia
220. Morphologic shifts in FAB phenotype at first relapse of childhood acute lymphoblastic leukemia
221. Morphologic changes in blast cells of children with acute lymphoblastic leukemia in relapse
222. Comparison of morphology of ALL at presentation and at relapse
223. Enzyme markers in acute leukemia: advances during the last decade
224. Prognostic value of 5′ nucleotidase in acute lymphoblastic leukemia with common ALL phenotype
225. 5′-Nucleotidase, adenosine deaminase and purine nucleoside phosphorylase activities in acute leukemia
226. Diminished lymphoblast 5′ nucleotidase activity in acute lymphoblastic leukemia with T-cell characteristics
227. Biochemical aspects of acute leukemia
228. Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia
229. Glucocorticoid receptors and steroid sensitivity in normal and neoplastic human lymphoid tissues: a review
230. Glucocorticoid receptors in lymphoid tumors
231. Glucocorticoid receptors in childhood acute lymphoblastic leukemia
232. Therapeutic and prognostic implications of glucocorticoid receptors and terminal deoxynucleotidyl transferase in acute leukemia
233. Impact of treatment efficacy on the prognostic value of glucocorticoid receptor levels in childhood acute lymphoblastic leukemia
234. The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia
235. Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia
236. Glucocorticoid sensitivity of human leukemic cells
237. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies
238. Prognostic significance of chromosomal abnormalities in acute leukemias and myelodysplastic syndromes
239. The chromosomes in human leukemia
240. Presence of clonal chromosomal abnormalities in virtually all cases of acute lymphoblastic leukemia
241. Prognostic importance of chromosome number of 136 untreated children with acute lymphoblastic leukemia
242. Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia
243. Isochromosome 17q in childhood acute lymphoblastic leukemia: an adverse prognostic feature in association with hyperploidy
244. Cytogenetics of acute lymphoblastic leukaemias in children as a factor in the prediction of long-term survival
245. Near-haploid acute lymphoblastic leukemia; a unique subgroup with a poor prognosis
246. Third International Workshop on Chromosomes in Leukemia, Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia
247. Translocation 4;11 acute leukemia; three case reports and review of the literature
248. Translocation 4;11 in acute lymphoblastic leukemia; clinical characteristics and prognostic significance
249. Clinical and biological features predict poor prognosis in acute lymphoid leukemias, a Pediatric Oncology Group study
250. Acute lymphoblastic leukemia in infants less than one year of age; a cumulative experience of the Childrens Cancer Study Group
251. Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin heavy chain genes
252. Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation
253. Acute leukemia associated with the t(4;11) chromosome rearrangement; ultrastructural and immunological characteristics
254. Pre-B cell leukemia associated with chromosome translocation 1;19
255. Gene for human insulin receptor: localization to site on chromosome 19 involved in pre-B cell leukemia
256. Locus of the alphachain of the T-cell receptor is split by chromosomal translocation in T-cell leukemias
257. A possible subgroup of ALL with 9p
258. Common and pre-B acute lymphoblastic leukemia cells express interleukin 2 receptors and interleukin 2 stimulates in vitro colony formation
259. Serum levels of interleukin 2 receptor (IL-2R) in childhood acute lymphoblastic leukemia
260. Relationship of pretreatment lymphoblast proliferative activity and prognosis in 97 children with acute lymphoblastic leukemia
261. Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukemia of childhood
262. Multiparameter flow cytometry for determination of ploidy, proliferation, and differentiation in acute leukemia: treatment effects and prognostic value
263. Cell kinetics of leukemia
264. RNA-content predicts early response in pediatric ALL: multivariate analysis of prognostic factors
265. Prognostic importance of blast cell DNA content in childhood acute lymphoblastic leukemia
266. Prognostic implication of hyperploidy as based on DNA flow cytometric measurement in childhood acute lymphocytic leukemia — a multicenter study
267. Aneuploidy and percentage of S-phase cells determined by flow cytometry correlate with cell phenotype in childhood acute leukemia
268. Cytotoxic effects of dexamethasone restricted to noncycling early G1 phase cells by L1210 leukemia
269. Stimulation of 3T3 cells induces transcription of the c-fos protooncogene
270. Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells
271. Expression of p53 in human leukemia and lymphoma
272. Expression of cellular oncogenes in human malignancies
273. Cyclin: a nuclear protein whose level correlates directly with the proliferative rate of normal as well as transformed cells
274. Rapid disappearance of statin, a nonproliferating and senescent cell-specific protein, upon reentering the process of cell cycling
275. Down syndrome and acute leukemia in children: a 10 year retrospective survey from Childrens Cancer Study Group
276. A comparative analysis of acute lymphocytic leukemia in white and black children: presenting clinical features and immunologic markers
277. Differences in the presentation of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in black children and white children
278. Statistical evaluation of prognostic factors in ALL and treatment results
279. Clonal abnormalities in acute lymphoblastic leukemia: comparison of cytogenetics and flow cytometry
280. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen, a new intensive therapy protocol; a report from the Childrens Cancer Study Group
281. Cell surface antigens. Prognostic implications in childhood acute lymphoblastic leukemia
282. Acute lymphoblastic leukemia: current status of therapy in children
283. Report and recommendations of the Rome Workshop concerning poor-prognosis acute lymphoblastic leukemia in children
284. Analysis of prognostic factors in acute lymphoblastic leukemia
285. Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia
286. Age at diagnosis in childhood acute lymphoblastic leukemia
287. The staging of childhood acute lymphoblastic leukemia: strategies of the Childrens Cancer Study Group and a three-dimensional technic of multivariate analysis
288. Prognosis and slow disappearance of blast cells in childhood acute lymphoblastic leukemia
289. FAB morphology and early response to induction therapy in childhood acute lymphoblastic leukemia (ALL)
290. Childhood acute lymphoblastic leukemia. II. Strategies and innovations for producing more cures
291. Acute leukaemia in children
292. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia
293. Acute lymphoblastic leukemia in childhood
294. Bone marrow transplantation in acute leukemia: recent advances and comparison with alternative therapies
295. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries
296. Acute lymphoblastic leukemia in children
297. Infection and transfusion therapy in acute leukaemia
298. A long-term follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens
299. Prognostic factors in acute lymphoblastic leukemia of childhood: CCG141
300. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group Study
301. 9/L
302. Comparison of intermediate-dose methotrexate with cranial irradiation in the post induction treatment of acute lymphoblastic leukemia
303. Application of the theoretical models to chemotherapy protocol design
304. Reduction in CNS leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. A report from CCSG
305. Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children
306. Therapy of acute lymphocytic leukemia in childhood with intermediate dose methotrexate and CNS irradiation
307. Intermediate dose methotrexate in the treatment of childhood acute lymphocytic leukemia: lack of benefit during maintenance therapy following intensive induction therapy
308. Central nervous system preventive therapy with systemic high dose methotrexate versus cranial radiation and intrathecal methotrexate. Longitudinal comparison of effects of treatment on intellectual function of children with acute lymphoblastic leukemia
309. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia
310. Neurological sequelae of methotrexate and ionizing radiation; a new classification
311. Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia; serial long-term follow-up
312. Neuropsychologic sequelae in irradiated (1800 rads) and non-irradiated children with acute lymphoblastic leukemia (ALL)
313. Are cognitive and educational development affected by age at which prophylactic therapy is given in acute lymphoblastic leukemia?
314. Central nervous system prophylactic treatment for childhood leukemia, neuropsychological outcome studies
315. Nine brain tumors as a late effect in children “cured” of acute lymphoblastic leukemia (ALL) from a single protocol
316. Brain tumors in survivors of childhood acute lymphoblastic leukemia
317. Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia
318. Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia
319. The Berlin childhood acute lymphoblastic leukaemia therapy study 1970–1976
320. Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
321. Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia. A report from BFM Study Group
322. Randomized study of 3 years versus 5 years of chemotherapy in childhood lymphoblastic leukemia
323. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: results of CCG-141
324. Detection of RNA transcripts in normal lymphoid colonies
325. Detection of minimal malignant cell infiltration in the bone marrow of patients with solid tumors, non-Hodgkin lymphoma, and leukaemias
326. Terminal deoxynucleotidyl transferase activity in childhood leukemia
327. Elective testicular biopsy during chemotherapy for childhood leukemia is of no clinical value
328. Clinical and occult testicular leukemia in long term survivors of acute lymphoblastic leukemia
329. Childhood acute leukemia: a search for occult extramedullary disease prior to discontinuation of therapy
330. Occult testicular leukemia
331. Isolated testicular relapse in boys with acute lymphoblastic leukemia: treatment and outcome
332. Isolated testicular relapse in acute lymphocytic leukemia of childhood: categories and influence on survival
333. Testicular infiltrates in children with acute lymphoblastic leukemia: a prospective study
334. TdT+ cells in routine testicular biopsy: significance and relation to histology and clinical outcome
335. Overt and occult testicular leukemia (OTL) after two years of continuous remission: diagnosis and treatment results
336. Diagnostic value of surgical testicular biopsy after therapy for acute lymphocytic leukemia
337. Sequential testicular biopsies in childhood acute lymphoblastic leukemia
338. Fate after occult testicular relapse (OTR) in childhood acute lymphoblastic leukemia
339. Treatment results for overt and occult testicular leukemia (COTL) diagnosed after 2 years of continuous remission
340. Ultrastructural criteria for evaluating leukemic infiltration in prepubertal testicular biopsies
341. Tdt+ cells in routine testicular biopsy: significance and relation to histology and clinical outcome
342. Terminal transferase positive cells in testicular biopsy specimens from boys with acute lymphoblastic leukemia
343. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse; a Pediatric Oncology Group study
344. A comparison of marrow transplantation with chemotherapy for children with acute lymphoblastic leukemia in second or subsequent remission
345. High dose cytosine arabinoside and fractionated total body irradiation: an improved reparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission
346. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during first complete remission
347. Bone marrow transplantation for acute lymphoblastic leukemia
348. Allogeneic bone marrow transplantation after hyperfractionation total-body irradiation and cyclophosphamide in children with acute leukemia
349. Depletion of T lymphocytes from donor marrow for the prevention of graft versus host disease following bone marrow transplantation, a prospective randomized trial
350. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with BA-1, BA-2, and BA-3 with complement
351. Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement
352. Autologous bone marrow transplantation in acute leukemia: a phase II study of in vitro treatment with 4-hydroperoxycyclophosphamide to purge tumor cells
353. Bone marrow transplantation has a limited role in prolonging second marrow remission in childhood lymphoblastic leukemia
354. Genetics of multidrug resistance
355. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukemia?
356. Prognostic relevance of clinical pharmacology of antileukemic drugs
357. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect